FLT3 and acute myeloid leukemia: Although FLT3 inhibitors significantly improve outcomes in AML patients with FLT3 mutations [26], whether they can improve the prognosis of patients with AML CEBPAbZIP-inf with FLT3 mutations needs further investigation.